In this BioPharm International interview, Joerg Zimmerman, director of process development and implementation at Vetter, discusses key considerations for commercializing a compound under development. The podcast includes case study examples, technical challenges faced during drug development, and sound advice to facilitate the process. Regulatory expectations for biological formulations in prefilled syringes as combination products and the need to establish compatibility at an early stage in development are also discussed.
Joerg Zimmerman, director of process development and implementation at Vetter discusses the need to think carefully about the commercialization efforts that must be applied to a compound under development. Providing real world examples, Zimmerman runs through the technical challenges that biotech companies commonly face in drug development and offers some sound advice to facilitate the process. Zimmerman also talks on the regulatory focus on considering biological formulations in prefilled syringes as combination products and the need to establish compatibility at an early stage in development. Posted Feb. 2012.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.